1. South Korea Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Pharmicell Co., Ltd

Pharmicell Co., Ltd

KKRX:005690
10,180.00
KRW
-460.00
(-4.32%)
775.55EPS
16.71P/E
777.65BMarket Cap
Nov 11Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
790.12
433.68
453.08
493.67
431.41
478.46
545.46
626.58
866.19
1,005.24
942.89
1,085.76
1,899.66
2,265.67
Basic EPS, GAAP
-607.88
-619
-115
-12
-376
-214
73
87
158
138
60
106
671
775.55
Free Cash Flow per Basic Share
-126.32
-240.55
-175.19
-50.75
-107.53
-21.47
-29.18
136.68
-159.53
-184.46
97.14
-14.06
558.99
435.25
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
19.99
- -
Book Value per Share
1,900.23
1,584.21
1,596.35
1,620.62
927
792.21
859.43
952.61
1,065.48
1,277.66
1,339.86
1,440.56
2,064.49
2,389.28
Tangible Book Value per Share
135.6
436.06
544.41
612.61
578.26
679.93
741.71
847.43
961.45
1,175.03
1,246.62
1,347.2
1,971.17
2,295.75
Basic Weighted Avg Shares
42
46
56
56
58
59
60
60
60
60
60
60
60
60
Sales/Revenue/Turnover
33,405
20,155
25,176
27,839
25,197
28,352
32,482
37,752
51,812
60,182
56,227
64,851
114,062
135,941
Operating Margin (%)
-22.86
-41.76
-21.97
-5.4
-18.09
0.92
6.05
19.16
15.18
14.74
2.3
7.18
30.08
32.42
Depreciation Expense
3,599
2,787
2,590
3,346
3,326
1,623
1,792
1,769
1,736
2,185
2,841
3,063
3,035
3,014
Net Income, GAAP
-25,701
-28,768
-6,390
-677
-21,961
-12,681
4,347
5,242
9,451
8,262
3,578
6,331
40,289
46,533
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
24.39
- -
- -
12.58
Profit Margin (%)
-76.94
-142.73
-25.38
-2.43
-87.16
-44.73
13.38
13.88
18.24
13.73
6.36
9.76
35.32
34.23
Working Capital
1,088
20,943
19,923
28,707
23,470
29,211
29,126
36,432
40,098
33,817
35,403
40,389
75,506
98,729
LT Debt
- -
- -
- -
- -
396
3,000
50
35
85
49
390
427
8,374
19,303
Total Equity
82,421
83,402
91,344
94,595
54,132
47,490
51,519
57,105
63,871
76,665
80,397
86,439
123,878
143,366
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
12.74
11.23
- -
1.12
- -
- -
27.99
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
9.28
15.76
- -
4.79
- -
- -
33.39
Return on Common Equity (%)
-27.92
-34.69
-7.31
-0.73
-29.53
-24.96
8.78
9.65
15.62
11.76
4.56
7.59
38.31
38.03

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
6,213
6,224
6,226
LT Borrowings
8,000
13,942
19,017
LT Finance Leases
374
344
286
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
60
60
60
Market Capitalization
871,858
875,459
777,652

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
95,128
107,554
114,788
Cash, Cash Equivalents & STI
56,844
60,096
65,670
Accounts Receivable, Net
20,745
29,915
29,059
Inventories
15,966
16,006
18,333
Total Current Liabilities
19,622
15,682
16,060
Payables & Accruals
- -
- -
- -
ST Debt
6,213
6,224
6,226
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
5.54%
17.52%
43.31%
Free Cash Flow
-513.11%
-912.57%
-4,095.77%
Net Income, GAAP
352.42%
124.87%
536.35%
Sales/Revenue/Turnover
18.24%
27.61%
75.88%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
10,973
17,811
14,595
21,473
64,851
2025
27,030
26,763
25,647
34,622
114,062
2026
36,692
38,980
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-23
46
12
69.23
106
2025
141
123
146.26
261.18
671
2026
195.1
173
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
19.99
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Hyun-Soo Kim
Full Time Employees
186
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Ssangbong Building Seoul SL South Korea
IPO Date
May 20, 1988
Website
pharmicell.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Pharmicell Co., Ltd. (005690.KS) is a biopharmaceutical company that develops and commercializes stem cell therapeutics and biochemical products primarily in South Korea and internationally. Founded in 1968 and headquartered in Seoul, South Korea, the company operates through two main divisions: Biopharmaceutical Business, which focuses on stem cell drugs such as the approved Cellgram-AMI, manufactured using autologous bone marrow-derived mesenchymal stem cells to improve ejection fraction in patients with acute myocardial infarction following coronary angioplasty; and Biochemical Business, which produces intermediates for raw material medicines including nucleosides, mPEGs, HDP-tosylate, and Vincelactam, as well as eco-friendly flame retardants, low dielectric constant materials, polyol synthesis catalysts, and PET catalysts. Its biopharmaceutical pipeline includes Cellgram-LC for liver disease, Cellgram-ED for impotence, Hearticellgram-AMI for cardiac disease, Cellgram-CKD for chronic kidney disease, and Cellgram-AKI for acute kidney disease; the company also offers stem cell banking services through its Twelve platform, contract manufacturing organization (CMO) and clinical development services for new drugs, Half-Serum DMEM culture media, and cosmetics derived from stem cell culture technology. Pharmicell serves healthcare providers, researchers, and industrial customers in the regenerative medicine, oncology, and chemical manufacturing sectors, with geographic operations centered in South Korea and extending to international markets for stem cell drugs and biochemical intermediates. In recent developments, the company continues to advance clinical trials for pipeline assets including acute ischemic stroke (Phase 3) and chronic spinal cord injury (Phase 2/3), alongside investigator-initiated trials for alcoholic cirrhosis, pulmonary fibrosis, and cancer therapies; it plans US trials for Livercellgram to address limited competition in myocardial infarction treatments. Formerly known as FcB2welve Co., Ltd., Pharmicell changed its name in September 2011 to reflect its focus on stem cell innovation, and maintains steady revenue from its biochemical segment to support biopharma R&D amid a dual business model.